DE60016803D1 - Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen - Google Patents

Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen

Info

Publication number
DE60016803D1
DE60016803D1 DE60016803T DE60016803T DE60016803D1 DE 60016803 D1 DE60016803 D1 DE 60016803D1 DE 60016803 T DE60016803 T DE 60016803T DE 60016803 T DE60016803 T DE 60016803T DE 60016803 D1 DE60016803 D1 DE 60016803D1
Authority
DE
Germany
Prior art keywords
calcium
system disorders
nervo
remedies
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60016803T
Other languages
English (en)
Other versions
DE60016803T2 (de
Inventor
Satoshi Yuki
Naruhiko Yoshii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of DE60016803D1 publication Critical patent/DE60016803D1/de
Publication of DE60016803T2 publication Critical patent/DE60016803T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60016803T 1999-12-21 2000-12-20 Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen Expired - Lifetime DE60016803T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP36268099 1999-12-21
JP36268099 1999-12-21
JP2000065272 2000-03-09
JP2000065272 2000-03-09
PCT/JP2000/009024 WO2001045739A1 (fr) 1999-12-21 2000-12-20 Remedes et/ou medicaments preventifs pour troubles du systeme nerveux

Publications (2)

Publication Number Publication Date
DE60016803D1 true DE60016803D1 (de) 2005-01-20
DE60016803T2 DE60016803T2 (de) 2005-12-29

Family

ID=26581413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016803T Expired - Lifetime DE60016803T2 (de) 1999-12-21 2000-12-20 Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen

Country Status (10)

Country Link
US (1) US7652017B2 (de)
EP (1) EP1249245B1 (de)
KR (1) KR100740477B1 (de)
CN (1) CN100486574C (de)
AT (1) ATE284711T1 (de)
AU (1) AU2398001A (de)
CA (1) CA2394633A1 (de)
DE (1) DE60016803T2 (de)
ES (1) ES2233493T3 (de)
WO (1) WO2001045739A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072097A1 (fr) * 2001-03-13 2002-09-19 Mitsubishi Pharma Corporation Remedes et/ou medicaments preventifs pour des cardiopathies ischemiques diabetiques
AR034887A1 (es) * 2001-07-25 2004-03-24 Mitsubishi Pharma Corp Medicamento inhibidor del sistema de intercambio sodio/calcio
CA2455858A1 (en) * 2001-07-30 2003-02-13 Mitsubishi Pharma Corporation Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
AU2003261968A1 (en) * 2002-09-06 2004-03-29 Mitsubishi Pharma Corporation Protective agents for transplanted organ
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
US20070129441A1 (en) * 2003-05-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
US20060142395A1 (en) * 2003-05-06 2006-06-29 University Of North Texas Health Science Center Modulation of intracellular calcium signaling by N-acylethanolamines
BR112022018565A2 (pt) * 2020-03-19 2022-11-16 Sea6 Energy Pvt Ltd Compósito, processo para preparar o compósito, artigo e processo para preparar o artigo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (de) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazin-Derivate, ihre Herstellung und Verwendung
US5053409A (en) * 1989-03-27 1991-10-01 Mitsubishi Kasei Corporation Aminobenzenesulfonic acid derivatives
JPH0686438B2 (ja) * 1989-03-27 1994-11-02 三菱化成株式会社 アミノベンゼンスルホン酸誘導体
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
EP0675883A1 (de) * 1992-12-22 1995-10-11 Smithkline Beecham Plc Piperidinderivate als calcium-kanal-blocker
CA2192731C (en) * 1995-12-15 2005-09-27 Chika Yamazaki Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof

Also Published As

Publication number Publication date
EP1249245A1 (de) 2002-10-16
AU2398001A (en) 2001-07-03
KR100740477B1 (ko) 2007-07-19
KR20020063254A (ko) 2002-08-01
WO2001045739A1 (fr) 2001-06-28
DE60016803T2 (de) 2005-12-29
ES2233493T3 (es) 2005-06-16
CN1434724A (zh) 2003-08-06
EP1249245A4 (de) 2003-06-11
US20030114427A1 (en) 2003-06-19
ATE284711T1 (de) 2005-01-15
US7652017B2 (en) 2010-01-26
CA2394633A1 (en) 2001-06-28
CN100486574C (zh) 2009-05-13
EP1249245B1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
GB0225474D0 (en) Therapeutic agents
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
DE60016803D1 (de) Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
DK1152757T3 (da) MMP-inhibitorer i bindevævsblödhed
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
SE9503476D0 (sv) New combination

Legal Events

Date Code Title Description
8364 No opposition during term of opposition